Krka has received a score of 55 out of 100 in the 2025 S&P Global Corporate Sustainability Assessment, according to an announcement made on December 3, 2025. The company stated that this independent score supports its ongoing efforts in sustainable management and ESG (environmental, social, and governance) practices.
In a statement, Krka said, “The received independent score reaffirms the outlined direction of the Krka Group’s sustainable management practises and ESG governance, where we prioritise our social responsibility and care for the health and well-being of patients. We provide them with access to high-quality, safe and effective medicines produced to the highest standards of good manufacturing practise. In this process, we place significant emphasis on environmental protection and reducing our environmental impact. In the governance of the Krka Group, we adhere to the highest standards of business ethics, integrity and transparent operations.”
The company also highlighted its development strategy through 2030. “This year, within the Krka Group Development Strategy until 2030, under the three strategic pillars, we have further outlined our commitment to providing uninterrupted access to medicines, developing innovative generic medicines for the treatment of chronic diseases, and value creation so that the positive impacts of our operations reach all Krka stakeholders. In this way, we fulfill Krka’s mission of Living a Healthy Life.The received score serves as both an encouragement and a commitment to further improve the sustainability practices in the Krka Group,” Krka added.
